诺华新一代眼科药物Beovu的神奇之处

The drug Beovu is a full VEGF-A inhibitor developed by Novartis' ophthalmology monopoly $Alcon. It is a new single-chain antibody fragment with high stability and solubility. Compared with ranibizumab (48kDa) and Eylea (115kDa), biologic drugs approved by the FDA for the treatment of wet AMD, Beovu (26kDa) has the smallest molecular weight. Animal experiments have shown that compared with ranibizumab and bevacizumab, it may reduce systemic side effects. So what is the magic of Novartis’ new generation ophthalmic drug Beovu?

Beovu is a new drug developed for the treatment of wet AMD. Alcon announced the data of Beovu's Phase II clinical study at the 38th Annual Macula Society Meeting in Scottsdale, Arizona, USA, showing that Beovu is equally effective as Aflibercept. At the same time, Beovu shows the potential to reduce the frequency of dosing and reduce the burden of treatment.

Clinical trial data shows that when patients use Beovu, they can control the disease with just one visit every 12 weeks. Based on FDA-approved indications, patients can have 8-week and 12-week dosing intervals after monthly injections of Beovu for 3 months.

In related trials, blurred vision, conjunctival hemorrhage, cataracts, eye pain, and vitreous floating syndrome were reported. If you are currently using Beovu, the editor here recommends that patients must take the correct medication according to the doctor's instructions. Some patients always think that the effect of the drug itself can be improved by simply increasing the dose of the drug, and they also think that the occurrence of side effects can be reduced by reducing the dose of the drug. However, this is not actually the case. If the dose of the drug is changed privately, it may cause more adverse reactions, so do not use the drug blindly.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.